NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair Pathway
NPRL2+ cisplatin (cis-diamminedichloroplatinum (II) [CDDP]) treatment effector caspase, caspase-3, is activated and PARP is cleaved. Therefore, our result that the combination treatment of NPRL2 and CDDP activates a caspase cascade and hyperphosphorylates H2AX suggests that this combination treatment can strongly enhance the apoptotic pathway. Adding NPRL2 treatment to CDDP significantly enhanced Chk2 and Chk1 kinase activity, and NPRL2+ CDDP treatment remarkably degraded the interaction of Cdc2 and cyclin B1, leading to the inactivation of the Cdc2/cyclin B1 complex and arrest in G2/M. The cells arrested at the G2/M phase ultimately promote apoptosis with characteristic nuclear fragmentation. This combination treatment strongly inactivates Cdc25A and Cdc25C, and phospho-Cdc2 (Tyr-15), an inactivated type of Cdc2, is clearly increased in NPRL2+ CDDP treatment.
Publication
NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair Pathway. (2010) Gitanjali Jayachandran, et al. PLoS One. 2010;5(8):e11994. Figure: F8.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | NPRL2 | NPRL2 | ncbigene_symbol | NPRL2 | 10641 |
| Homo sapiens | Primates | ATM | ATM | ncbigene_symbol | ATM | 472 |
| Homo sapiens | Primates | Chk1 | CHK1 | ncbigene_synonym | CHEK1 | 1111 |
| Homo sapiens | Primates | Chk2 | CHK2 | ncbigene_synonym | CHEK2 | 11200 |
| Homo sapiens | Primates | Cdc25A | CDC25A | ncbigene_symbol | CDC25A | 993 |
| Homo sapiens | Primates | Cdc25C | CDC25C | ncbigene_symbol | CDC25C | 995 |
| Homo sapiens | Primates | G2 | G2 | ncbigene_synonym | WARS1 | 7453 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Cisplatin | Cisplatin | mesh:D002945 | cisplatin | chebi:27899 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|